The Call from ausbiz

Speakers debate small-cap medtech, REITs, and SaaS valuations amid market volatility

59 min Listen to the original Episode page
AVITA MedicalAquirinDe.memHealthCo Healthcare and Wellness REITReadyTechSRG GlobalNova Eye MedicalMotio

Summary

Speakers discuss US market volatility driven by AI trade deleveraging and political shifts. AVITA Medical is introduced as Stock of the Day, having upgraded full-year revenue guidance following strong Q3 sales growth of 53% year-on-year to US$26.1 million. Both speakers recommend selling AVITA Medical, arguing the stock is overvalued relative to its profitability stage, citing high multiples (5x EV/Sales) and funding risks despite improving cash flow. They prefer peers like Aurora Biosurgery or Polynovo. Aquirin is recommended as a buy due to significant contracts and low valuation. Views on De.mem are mixed, with one speaker recommending buying and the other advising selling or avoiding. HealthCo Healthcare and Wellness REIT is highlighted as a buy due to the resolution of its anchor tenant's issues and a significant discount to Net Tangible Assets. ReadyTech is viewed as a buy by one speaker but disagreed with by the other, who cites operational disappointments. SRG Global is viewed with caution by both speakers, with one labeling it expensive and warning of a potential cycle peak in contractors. MotorCycle Holdings is viewed as a nervous hold due to discretionary spending risks, while Propel Funeral Partners is seen as low-growth with high debt and lower margins than expected, raising concerns about leverage and competitive positioning against Invocare.

Key takeaways

  1. 1
    The US market is identified as the most lucrative for medical technology companies, offering better scale opportunities than Australia or Europe.

    Unidentified speaker (speaker_1) · 30:44

Episode sections

  1. 0:23 – 4:22

    Market Context and AVITA Medical

    Speakers discuss US market volatility driven by AI trade deleveraging and political shifts. AVITA Medical is introduced as Stock of the Day, having upgraded full-year revenue guidance following strong Q3 sales growth of 53% year-on-year to US$26.1 million.

  2. 4:22 – 9:07

    AVITA Medical Analysis

    Both speakers recommend selling AVITA Medical. They argue the stock is overvalued relative to its profitability stage, citing high multiples (5x EV/Sales) and funding risks despite improving cash flow. They prefer peers like Aurora Biosurgery or Polynovo.

  3. 9:07 – 14:08

    Mojo (MXO) Acquisition

    Mojo is discussed in the context of its takeover by IVE Group for six cents per share in cash. Speakers treat the holding as quasi-cash, noting delisting is expected in mid-December. IVE Group is viewed as having structural headwinds.

  4. 14:08 – 19:38

    Aquirin (AQN) Mining Services

    Aquirin is recommended as a buy. It has secured significant contracts, including a $40 million deal with Bright Star Resources and a $32 million deal with SMS Mining. Speakers highlight its low valuation (5-6x EV/EBITDA) and high earnings growth potential.

  5. 19:38 – 24:33

    De.mem Ltd (DEM) Water Treatment

    Mixed views on De.mem. Luke Winchester recommends buying, citing positive free cash flow and recurring revenue. Ben Richards advises selling/avoiding, arguing the business is not scalable, capital constrained, and lacks the asymmetric upside required for small-cap investing.

  6. 24:33 – 28:12

    Airtasker (ART) Marketplace Model

    Airtasker is discussed with skepticism regarding its business model. Speakers note it is a lead-generation platform rather than recurring revenue, with high churn risk. While the Australian business is profitable, international expansion is dilutive and unprofitable.

  7. 28:12 – 30:14

    Motio (MXO) Analysis

    Speaker 1 describes Motio as a difficult business to understand due to non-cash charges from media equity deals causing P&L swings. The US segment is struggling with falling growth rates, while the UK segment shows potential. A strategic review exiting the US market is seen as a key catalyst.

  8. 30:14 – 37:27

    Nova Eye Medical (EYE) Discussion

    Luke Winchester identifies Nova Eye Medical as a buy, citing its transition to profitability and growth in the lucrative US market. Ben Richards expresses skepticism, noting low market share, balance sheet risks, and competition from larger players, recommending a hold instead.

  9. 37:27 – 42:58

    HealthCo Healthcare and Wellness REIT (HCW) Review

    Ben Richards highlights HCW as a buy due to the resolution of its anchor tenant's (Healthscope) issues, reinstated distributions, and a significant discount to Net Tangible Assets (NTA). Luke Winchester agrees, noting the attractive yield and potential for capital gains despite the REIT sector risks.

  10. 42:58 – 46:54

    ReadyTech (RDY) Evaluation

    Luke Winchester views ReadyTech as a buy at current levels, arguing it is a mature SaaS business rather than high-growth tech, and suggests management should focus on shareholder returns. Ben Richards disagrees, citing operational disappointments and preferring higher-quality software peers like Catapult or SiteMinder.

  11. 46:54 – 50:21

    SRG Global (SRG) Assessment

    Both speakers express caution on SRG Global, with Ben Richards labeling it expensive at 21x earnings and warning of a potential cycle peak in contractors. Luke Winchester agrees, suggesting investors take profits due to the risk of contract failures and unsustainable multiples for the sector.

  12. 50:21 – 55:22

    MotorCycle Holdings (MTO) and Propel Funeral Partners (PFP) Overview

    MotorCycle Holdings is viewed as a nervous hold due to discretionary spending risks, though it is a dominant player. Propel Funeral Partners is seen as low-growth with high debt and lower margins than expected, raising concerns about leverage and competitive positioning against Invocare.

  13. 55:22 – 56:20

    De.mem Ltd (DEM) Valuation and Growth Concerns

    Speaker_2 questions whether recent weakness is structural, noting the stock trades at 17x earnings with a dividend yield above 5%. The speaker suggests it is cheap but lacks confidence in a return to earnings growth, recommending a hold or avoid.

  14. 56:20 – 59:18

    De.mem Ltd (DEM) Business Model Critique

    Speaker_1 criticizes the business model as purely private-to-public arbitrage without operational or brand synergies. They note earnings have plateaued around 20 million NPAT and debt is maxed out, recommending a sell until the PE ratio drops further.

Claims worth verifying

AVITA Medical reported Q3 revenue of US$26.1 million, up 53% year-on-year, bringing nine-month revenue to just over US$67 million (up 24%).

Andrew Gagan ·4:47

How to verify: AVITA Medical (ASX: AVH) Q3 FY26 Financial Report or Press Release available on the ASX website or company investor relations page. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Primary source

AVITA Medical reported quarterly cash use of $600,000 and targets cash flow break-even in the December quarter.

Andrew Gagan ·5:07

How to verify: AVITA Medical (ASX: AVH) Q3 FY26 Financial Report or Press Release available on the ASX website or company investor relations page. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Mojo (MXO) is being acquired by IVE Group in an all-cash scheme of implementation at six cents per share.

Unidentified speaker (speaker_1) ·10:28

How to verify: Mojo (ASX: MXO) and IVE Group (ASX: IVE) takeover scheme documents and press releases available on the ASX website. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Aquirin (AQN) has a $40 million, three-year contract with Bright Star Resources for operations in the Goldfields hub.

Unidentified speaker (UNKNOWN) ·15:43

How to verify: Aquirin (ASX: AQN) contract announcement press release available on the ASX website or company investor relations page. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Aquirin (AQN) announced a $32 million deal with SMS Mining Services over two years.

Unidentified speaker (speaker_2) ·16:25

How to verify: Aquirin (ASX: AQN) contract announcement press release available on the ASX website or company investor relations page. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Aquirin (AQN) trades at approximately 5-6 times EV to EBITDA, compared to peers at 7.5-8 times.

Unidentified speaker (speaker_2) ·17:46

How to verify: Calculated using Aquirin's market capitalization and EBITDA from its latest financial report, compared to peer company filings. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Primary source

Airtasker (ART) gross marketplace volume surged more than 20% year-on-year in its recent trading update.

Andrew Gagan ·27:37

How to verify: Airtasker (ASX: ART) October 2026 Trading Update or Q3 FY26 Financial Report available on the ASX website or company investor relations page. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

The VIX (volatility index) skyrocketed over the last week prior to the recording.

Unidentified speaker (speaker_2) ·3:12

How to verify: CBOE VIX historical data for the week leading up to November 6, 2026. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

AVITA Medical's shares re-rated from 2.5x EV to Sales to 5x EV to Sales.

Unidentified speaker (speaker_2) ·6:58

How to verify: Calculated using AVITA Medical's share price movement and trailing twelve-month sales figures from its financial reports. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Motio's US growth rate fell from over 100% year-on-year to 27% in Q1 2027.

Unidentified speaker (UNKNOWN) ·29:01

How to verify: Check Motio's (MXO) quarterly financial reports for Q1 2026 revenue growth figures for the US segment. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Nova Eye Medical has grown revenue 25-30% over the last four or five years.

Unidentified speaker (speaker_1) ·31:04

How to verify: Review Nova Eye Medical's (EYE) historical financial statements and annual reports from 2026-2026. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Nova Eye Medical has 70% gross margins.

Unidentified speaker (speaker_1) ·31:44

How to verify: Check Nova Eye Medical's (EYE) most recent quarterly or annual financial report for gross profit margin. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

HealthCo Healthcare and Wellness REIT (HCW) NTA was $1.35 as at 30 June.

Unidentified speaker (UNKNOWN) ·39:27

How to verify: Review HealthCo Healthcare and Wellness REIT's (HCW) half-year or annual financial report for the period ending 30 June. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Primary source

HCW shares trade at a 48% discount to book value.

Unidentified speaker (UNKNOWN) ·39:31

How to verify: Calculate the discount by comparing HCW's share price at the time of the podcast to its reported NTA per unit. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

ReadyTech was offered a bid at $2.00 cash.

Unidentified speaker (UNKNOWN) ·44:51

How to verify: Check ASX announcements for ReadyTech (RDY) regarding takeover bids or offers around the time of the podcast. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

MotorCycle Holdings has approximately 20% market share of new cars in Australia.

Unidentified speaker (speaker_1) ·50:51

How to verify: Review MotorCycle Holdings' (MTO) investor presentations or industry reports on Australian vehicle market share. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Propel Funeral Partners is growing top line at 1%.

Unidentified speaker (UNKNOWN) ·54:16

How to verify: Check Propel Funeral Partners' (PFP) most recent financial report for revenue growth rate. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Propel Funeral Partners has net debt to EBITDA creeping above three times.

Unidentified speaker (speaker_2) ·55:02

How to verify: Review Propel Funeral Partners' (PFP) most recent financial report for net debt and EBITDA figures to calculate the ratio. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

De.mem Ltd trades on about 17 times earnings, which is about as low as it's ever traded.

Unidentified speaker (speaker_2) ·55:37

How to verify: Check current P/E ratio and historical P/E range via ASX announcements or financial data providers like Bloomberg/Refinitiv for ticker DEM.AX. For recent events, verify 2026-08-06 through 2026-11-06. Use another period only when the speaker explicitly names it.

Do your own research

  • Verify AVITA Medical's Q3 sales figures and full-year revenue guidance in their latest ASX announcements or financial reports.
  • Check Aquirin's contract details with Bright Star Resources and SMS Mining, including payment terms and project timelines, via ASX filings.
  • Review HealthCo Healthcare and Wellness REIT's latest quarterly report for Net Tangible Assets (NTA) per share and distribution coverage ratios.
  • Compare ReadyTech's valuation multiples (EV/ARR or P/E) against peers like Iris, Hansen, WiseTech, Catapult, and SiteMinder using financial data providers.
  • Assess SRG Global's contractor backlog and historical contract failure rates to evaluate the 'contractor bubble' risk cited by speakers.
  • Examine Nova Eye Medical's balance sheet for cash reserves and debt levels, and compare its market share against larger US medtech competitors.
  • Check Motio's US segment revenue growth trends and non-cash charges from media equity deals in recent quarterly reports.
  • Review Propel Funeral Partners' debt-to-equity ratio and margin trends compared to competitor Invocare.
Full transcriptexpand
0:23
Unidentified speaker (UNKNOWN): G'day,
0:23
Andrew Gagan: welcome to the call ten 10 stocks picked by you, two 2 experts, one hour. It is Friday, the 6th of November. I'm Andrew Gagan. Thanks for joining us. And uh today, small cap special, and we are joined by Ben Richards from Seneca Financial Solutions and Luke Winchester from Merriweather Capital. Gentlemen, welcome
0:43
Andrew Gagan: to you both.
0:44
Unidentified speaker (UNKNOWN): Uh
0:45
Andrew Gagan: goodness, can should we just take a breath? Um, what just happened on on Wall Street? Um Uh we are seeing um yeah, time of recording, we're seeing some negative moves locally, but nearly not as so much as what we saw on Wall Street, of course. Uh Luke, how would you describe that session? And obviously, this all comes off the back of investors now,
1:04
Andrew Gagan: considering that with the Democrats taking control of Congress, that is going to be a negative for that AI build
1:10
Unidentified speaker (UNKNOWN): out.
1:11
Unidentified speaker (speaker_1): Yeah, look, fundamentally there are uh a few. comments from Democratic senators and and politicians talking about AI, talking about that build out and and potential guardrails or or you know slowing down the progress of things. That's the that's the tinder. But but the US market, I mean, w we need to get used to these sorts of moves. The
1:31
Unidentified speaker (speaker_1): US market, uh, far beyond what we see here on the ASX, um, really driven by leverage hedge funds on options. Uh, you get these outsized moves, and and so for me, I I look across what happened last night, and you know, it's really just a deleveraging event. You've had people crowded into a very thin range of stocks for quite a while around the
1:51
Unidentified speaker (speaker_1): AI trade. Um, and then it just becomes a rush for the exit as as people you know uh try to to beat the rush out. Others are forced to, you know, through those deleveraging as I was talking about before, and you just get this cast. cascading effect. It did sort of bleed through into some other sectors, um, you know, and it was a it was a pretty rough day. But as we're sort of seeing here, I mean, yeah,
2:11
Unidentified speaker (speaker_1): okay, um markets off a little bit, um, but you know, other other sectors holding up okay. We just don't have that same level of concentration and exposure, particularly to AI, that they do over in the US. So
2:22
Unidentified speaker (UNKNOWN): I
2:23
Unidentified speaker (speaker_1): look through this, Andrew, is it is it the the the start of something worse? It could well be I mean it's it's it's very difficult to sit here and say what the market's gonna do in the short term. But um I've almost become a little bit desensitized, I must admit, to these sorts of moves, particularly in that US market, just given it's so so leveraged and driven by algorithms and um, you know, really, really volatile
2:42
Unidentified speaker (speaker_1): moves.
2:43
Andrew Gagan: So Ben, um goal golden and rule of uh investing, don't panic. And we saw plenty of that overnight. Um
2:51
Andrew Gagan: would you be adjusting your portfolio? I mean, I'm not sure how much exposure you have to tech. Um, certainly here there is not much to get across. Um, nonetheless, how are you viewing
3:01
Unidentified speaker (UNKNOWN): it?
3:02
Unidentified speaker (speaker_2): Yeah, Andrew, I think uh there's one probably one constant in markets, and that's the fact that people will panic. Uh and yeah, sure enough,
3:11
Unidentified speaker (UNKNOWN): as
3:12
Unidentified speaker (speaker_2): we've seen over the last week, that the VIX, the volatility. index is is skyrocketing again. Uh, people kind of aren't sure which way to to pull in terms of long or short or US or or global markets. But yeah, I think it's not super surprising that this semiconductor boom has kind of uh
3:31
Unidentified speaker (speaker_2): ground to a halt, at least in the short term. Uh yeah, I think was as soon as you start to talk to people who are uh swearing off investing every end in the A on the on the ASX and and just doing US because that's going to outperform in perpetuity, you know you're probably closer to the top than the bottom. Um obviously the ASX is
3:50
Unidentified speaker (UNKNOWN): a
3:51
Unidentified speaker (speaker_2): different market by by concentration. We don't really have a lot of direct exposure to to some of this um these offshore moves, but
3:59
Unidentified speaker (UNKNOWN): yeah,
3:59
Unidentified speaker (speaker_2): the ASX is treated as a risk on market, so you do get flow. through particularly in the the materials and and some of the the contractors and other sort of adjacent exposure to to AI and US large cap tech build out. So yeah, certainly not immune, but uh as always just trying to pick stock specifics uh and and position
4:19
Unidentified speaker (speaker_2): the portfolio uh the best we can for the current environment.
4:22
Andrew Gagan: All Alright, right, picking stock specifics that's why we're here today. Uh bearing in mind this is
4:27
Unidentified speaker (UNKNOWN): a
4:28
Andrew Gagan: focus on small caps, given we have uh Ben and Luke with us. So let's get going with our stock of the day. It is um in the small cap space, it is Vita Medical. It's uh making news today. Uh has upgraded its full-year revenue guidance for a second consecutive quarter following a strong lift in third quarter sales. The regenerative medicine
4:47
Andrew Gagan: company reporting third-quarter third quarter revenue of 2016. 26.1 million US, that's up 53% on the prior corresponding period, taking nine-month revenue to just over 67 million US. That's a 24% jump. The company also reporting quarterly cash use of just 600,000, maintaining its target of reaching cash flow break-even
5:07
Andrew Gagan: in the December quarter. So strong financial results.
5:12
Unidentified speaker (UNKNOWN): Ben,
5:12
Andrew Gagan: how do you view
5:13
Unidentified speaker (UNKNOWN): it?
5:14
Unidentified speaker (UNKNOWN): Yeah,
5:15
Unidentified speaker (speaker_2): probably not the best day to put out an upgrade, uh, but therein is maybe the opportunity. But yeah, it's not for us, Avito. It's uh the the the third quarter growth looks pretty good, but
5:27
Unidentified speaker (UNKNOWN): if you
5:27
Unidentified speaker (speaker_2): actually look at the nine-month, it's it's actually sort of cycling, probably a weaker comparable period. Uh it's still growing top line at 25% over that nine-month period. Uh, and the financial performance is starting to improve. and look pretty good for this business. Uh it's got this resell uh skin regeneration
5:46
Unidentified speaker (speaker_2): technology. It allows your surgeon to take a small sample of patient skin and use it to treat the larger wound area, uh, particularly in sort of severe burns. But yeah, these skin repair stocks have been a bit of a graveyard of shareholder value over the longer term on the air. ASX. Look at um
6:04
Unidentified speaker (UNKNOWN): not
6:04
Unidentified speaker (speaker_2): only Evita but also Polynovo and Aurora is the other one.
6:08
Unidentified speaker (UNKNOWN): Uh
6:09
Unidentified speaker (speaker_2): you'll find that as soon as they sort of have a sniff of profitability, they continue to aggress uh aggressively invest in sort of product rollout or in uh developing a new product which is quite capital intensive. So it's probably not as uh
6:25
Unidentified speaker (UNKNOWN): you don't
6:26
Unidentified speaker (speaker_2): get as much opportunity. operating leverage as people think. I mean, they're demonstrating a bit of operating leverage here, but
6:31
Unidentified speaker (UNKNOWN): uh
6:32
Unidentified speaker (speaker_2): there's very few examples, particularly in the small cap end, which show sustained operating leverage, I would say.
6:38
Unidentified speaker (UNKNOWN): Um
6:39
Unidentified speaker (speaker_2): and it's still generating losses here. So AVITA's improving, the shares have re rated materially because it looks like it's getting closer to that break break-even point, but not quite there yet. Uh obviously, when you're still burning. cash, there's there's funding risk. So maybe you can get a bit of a re-rate on that, but looks like it's kind of already priced in here. Uh the stock's
6:58
Unidentified speaker (speaker_2): rerouted from two and a half times EV to sales to five times. So yeah, we'd we'd be taking profits here, recycling into other opportunities, of which there are no shortage of opportunities in this current market, Andrew.
7:10
Andrew Gagan: Indeed. All right, so I'll take that as a sell then from you. Look for uh taking some profit there. moving elsewhere. Luke, what would you do with
7:17
Unidentified speaker (UNKNOWN): it?
7:19
Unidentified speaker (UNKNOWN): Um
7:19
Unidentified speaker (speaker_1): a Vita, sorry, had a had a few technical issues there. Um look, I had a Vita come up on this program as stock of the day a few months ago, Andrew. And look at that chart there. I reckon I had it back in uh maybe June, July, August, somewhere around at that bottom. They just had a pretty bad quarter, and I I sort of said, you know, this looks like a bit of a broken business to me. Revenues had stagnated, generating heavy
7:39
Unidentified speaker (speaker_1): quarterly losses. Um, and then I'd sort of forgotten about this one until someone mentioned it the other day. I look at the chart, and you
7:46
Unidentified speaker (UNKNOWN): know,
7:46
Unidentified speaker (speaker_1): you had a four-bagger if you ignored my advice back then and went and bought the stock. Um, look, the results have been good, but certainly um nothing to to me that would warrant this sort of share price move. I think the market's really getting ahead of itself here and um really extrapolating the growth. over the last two quarters, not just out into the near future,
8:07
Unidentified speaker (speaker_1): but out into that medium longer term as well. 700 odd mil market cap. They're calling for cash flow positive, but there's still some um uh still some um yeah P and L cost below that. They'll still be having uh you know an E bit loss for for quite a while. Um I I don't really prefer peers directly in the space, as in I'd say you know, go and buy something.
8:27
Unidentified speaker (speaker_1): else, but I have looked at a few others. I would probably prefer something like an Aurora biosurgery. Don't own it. That's just uh my view. And even Polynovo looks a bit more attractive than this. Um, yep, I'll say uh a take profit slash a sell for this one as well.
8:42
Unidentified speaker (UNKNOWN): Righto,
8:43
Andrew Gagan: that is a double sell then. Taking profit on a Vita Medical seeing opportunity elsewhere, particularly if you want to get into that particular space.
8:49
Unidentified speaker (UNKNOWN): All
8:50
Andrew Gagan: Alright,
8:50
Unidentified speaker (UNKNOWN): right,
8:50
Andrew Gagan: that's our. stock of the day. Let's uh turn now to the first five. As chosen by you, uh, we are going to get across Mojo Aquarium Limited DMEM, Airtasca, and Nova I Medical. So let's begin with Mojo.
9:07
Andrew Gagan: And uh look, this is in the um
9:12
Unidentified speaker (UNKNOWN): well,
9:12
Andrew Gagan: it's um AV A V essentially.
9:15
Andrew Gagan: um digital place based out of home media company um essentially operating across the country. Um but it um it's been taken over. I've group uh in a scheme of implementation currently uh that's uh took effect in uh late December there, so it's uh acquiring 100%
9:36
Andrew Gagan: of the company's shares. Now that takes us to the question. question. In fact, Nick saying, Um, hi look, love to get your thoughts on the recent acquisition of Mojia by Ive Group. Doesn't mean they will take uh take it off the ASX. I hold it and wonder whether to keep holding or sell and look for other opportunities. And would uh Ive Group
9:56
Unidentified speaker (UNKNOWN): uh
9:56
Andrew Gagan: be a reestimal Read as to more buy?
9:58
Unidentified speaker (UNKNOWN): Uh
9:59
Andrew Gagan: of course, this is not um investment advice, purely. information only. Luke, given it was directed at you, what do you think?
10:08
Unidentified speaker (speaker_1): Yeah, we can't give direct advice to Nick, but I can certainly talk to my experience. So we own Mosheo, it was a decent sized position in the fund. Had a takeover bid as Nick pointed out, an all-cash offer at six cents from IVE Yeah, Group, um fellow listed business, uh, which looks like it will go through. It's got full board approval. um, you know, has
10:28
Unidentified speaker (speaker_1): to go through all the regulatory steps, but I I don't see anything that would probably disrupt it from here. Um so to answer Nick's first question, yep, this will almost certainly get delisted in early mid-December. You'll get your six cents cash from IVE group. Should you hold or sell today? I mean, it's the the same way you would play any of these businesses that are under takeover where you've got
10:48
Unidentified speaker (speaker_1): a a scheme in place and and no real question. marks over FIRB financing or anything like that. So I'm treating this as sort of quasi-cash in the in the portfolio. Um, you know, can liquidate it pretty quickly. Um, have sold a little bit into it. I it's again just something that I like to do when you get sort of these bids because they can fall through for some other reason sometimes
11:08
Unidentified speaker (speaker_1): out of left field. So um sold about a quarter, a little bit over of the position, holding the rest, uh, but sort of treating it a little bit like cash in the portfolio. The potential for a higher bid is there, but as sort of time goes on, we get closer and closer to that early mid-December date. It's less and less likely. So Nick, yep, won't give any advice, you know, sp specifically, but that's
11:28
Unidentified speaker (speaker_1): sort of how I've approaching the fund. As for IVE Group, come up a few times on the program. I don't mind the business. It's it's one of those ones that's sort of uh really in not maybe not a terminal decline. but has structural headwinds against it. I think you get a good dividend yield out of it and that's probably the only reason you'd hold it. And that's not why I own Modeo. So I wouldn't look at IVE group as as
11:48
Unidentified speaker (speaker_1): a direct comparison and look to pivot across from that point of view.
11:52
Andrew Gagan: All right. So it
11:54
Unidentified speaker (UNKNOWN): I'll
11:54
Unidentified speaker (speaker_1): say a hold for the program, but but yep,
11:56
Unidentified speaker (UNKNOWN): you
11:56
Unidentified speaker (speaker_1): know, if you've got a better idea that pops up in this sort of market, um, you yeah, know, that's your that's your cash to to raise and and go in.
12:01
Unidentified speaker (UNKNOWN): Yep,
12:02
Andrew Gagan: that makes sense. All right. Uh Ben, thoughts?
12:05
Unidentified speaker (UNKNOWN): Yeah,
12:06
Unidentified speaker (speaker_2): well Luke's the uh the motion guru let's say but I suppose a couple comments from from our end. One is
12:13
Unidentified speaker (UNKNOWN): uh
12:13
Unidentified speaker (speaker_2): it's a bit of a common theme. You're seeing a lot of these sort of beaten down micro caps uh sort of trade down over the longer term with little investor interest and and not that much trading liquidity until such a point where they get a tag a takeover bid, often in cash. Uh particularly I've looks kind of cheap, so they wouldn't really want to issue
12:33
Unidentified speaker (speaker_2): script for this acquisition. They're more likely to do cash.
12:36
Unidentified speaker (UNKNOWN): But
12:37
Unidentified speaker (speaker_2): um yeah, it's kind of just always looked a bit sub scale for us. So
12:41
Unidentified speaker (UNKNOWN): yeah,
12:41
Unidentified speaker (speaker_2): they acquired uh um some assets and have been growing profitably in that sort of outdoor advertising um at venue advertising space, which probably a little bit underrated. Um you're still seeing the likes of of double H uh and those guys kind of do
13:01
Unidentified speaker (speaker_2): okay and and also generate pr uh takeover interest. So probably not the worst sector to be in. Uh now it's taken over. Looked like a bit of a skinny premium from memory uh to I suppose the potential of this business. So
13:14
Unidentified speaker (UNKNOWN): um
13:14
Unidentified speaker (speaker_2): uh maybe a little disappointing, but probably looks like there'll be no other bidder as far as we can see. Um, so yeah, decent result in the short term. In the long term, it's probably just not one for us. Uh, you need to be super high conviction to to kind of deal with that level of illiquidity, uh, and it's just not one that we think
13:34
Unidentified speaker (speaker_2): probably has the the growth or the the asymmetric upside to kind of warrant injury. interest. So yeah, I'd be probably taking profits into the takeover bit as well.
13:44
Unidentified speaker (UNKNOWN): Uh
13:45
Andrew Gagan: so it's more likely a sell from you then.
13:48
Unidentified speaker (UNKNOWN): Uh
13:48
Andrew Gagan: let's call that a hole in the cell for uh Mode Mosho. Modeo. Um all right. Let's now turn to Aquarium Limited. Jamie asking about this one. Uh so this is a mining services, particularly with focus on drilling and blasting.
14:08
Andrew Gagan: And in fact,
14:11
Andrew Gagan: it's just activated its um drill force business there. That's its drilling division. Particularly it's got a program going on with Bright Star Resources at the moment. Ben, have you looked at
14:22
Unidentified speaker (UNKNOWN): this?
14:24
Unidentified speaker (speaker_2): Have indeed and own it. I will
14:26
Unidentified speaker (UNKNOWN): just
14:26
Unidentified speaker (speaker_2): quickly uh point out that it's Aquirin, as in N for Nelly rather than Aquarium. Oh,
14:31
Andrew Gagan: I was gonna say,
14:32
Unidentified speaker (UNKNOWN): because it sounded technically.
14:38
Andrew Gagan: Okay, we've got a typo. Let's uh Lex Correct.
14:41
Unidentified speaker (speaker_2): That's all good. Aquirion, it's um really interesting business uh and probably, as the name shows, quite under the radar. I don't think don't think a lot of people are really across this one, but
14:53
Unidentified speaker (UNKNOWN): uh
14:54
Unidentified speaker (speaker_2): they've been stacking together some nice contract wins. So these guys are kind of drill and blast experts, uh vertically integrated, so they've got a uh production facility where they're producing explosives for for drill and blast, and that's been going pretty well. So they've got contracts with where that they're tolling for Dino Noble,
15:13
Unidentified speaker (UNKNOWN): uh
15:14
Unidentified speaker (speaker_2): which is the old Instatec pivot. So that's increasing volume steadily and generating profit for them.
15:20
Unidentified speaker (UNKNOWN): Uh,
15:20
Unidentified speaker (speaker_2): and they've also got some technology of which they're commercializing through this thing called Drill Force, where they do the drill and blast services, uh, and they basically use the different bits of their business to supply
15:31
Unidentified speaker (UNKNOWN): uh
15:31
Unidentified speaker (speaker_2): themselves for those contracts. So they've won a couple of those. They've got uh the Orion Orien Group uh gold mine in WA, which is a sort of little known but privately held uh cash machine
15:43
Unidentified speaker (UNKNOWN): in
15:43
Unidentified speaker (speaker_2): the the Mount Ida region. And they've also importantly stacked on Bright Star. So that's a 40 million three year contract with with Lord Byron, Bright Star's operations in the Goldfield Goldfields hub. But there's a lot of scope to expand that out as you look to kind of the the Corktree Well, Lady Shanton, Shenton, and they're also.
16:03
Unidentified speaker (speaker_2): they've also got um
16:05
Unidentified speaker (UNKNOWN): the
16:05
Unidentified speaker (speaker_2): Sandstone project as well, which they've been drilling out and looks to be really material in terms of resource and future production. So a lot of scope to grow that we think. Uh and then most recently they've announced a deal with SMS Mining Services. So that's a $32 thirty-two million dollar deal over two
16:25
Unidentified speaker (speaker_2): years.
16:26
Unidentified speaker (UNKNOWN): Uh this
16:26
Unidentified speaker (speaker_2): is another super interesting one. So for the uh the gold nerds that kinda look at all these little developers and see if there's any value in 'em, uh, such as ourselves, we've been looking at this area
16:37
Unidentified speaker (UNKNOWN): uh
16:37
Unidentified speaker (speaker_2): where they're return they're turning on the turning back on the Kirkalocker mill. So there's quite a few juniors that uh have announced tolling arrangements with this Kirkalocker Kirk Locker mill. It's currently being it's owned by um I think a Singaporean private equity group. So they got plenty of cash. They've got incentive to turn it back on and get it get it humming.
16:57
Unidentified speaker (UNKNOWN): Uh
16:57
Unidentified speaker (speaker_2): and there's a lot of work to be done in that area. So yeah, Quirin's kind of got three or four pretty decent sized contracts now. Uh and it's hit that earnings inflection point. So really tiny market cap. I think it's sub fifty 50 mil, it might be
17:12
Unidentified speaker (UNKNOWN): what,
17:13
Unidentified speaker (speaker_2): forty 44 four mil at about thirty 30, 33, 34 cents. It was trading the other day. So yeah, super cheap. Uh they've got a they've got cash. They've got a facility with NAB bank to to fund that growth.
17:26
Unidentified speaker (UNKNOWN): Uh
17:27
Unidentified speaker (speaker_2): and it trades on a really, really low valuation as far as we're concerned. So it's on about five or six times EV to EBITDA versus peers of sort of eight times, seven and a half, eight times. Uh and it offers earnings K Gar, compound annual growth rate of 50% versus those peers on about
17:46
Unidentified speaker (speaker_2): 16. So it's quite a small business and early stage in that execution. But not only do we think it's cheap on the current contracts, but think it's got really good
17:57
Unidentified speaker (speaker_2): opportunity with its current uh people and asset base to to win more contracts. So probably over the next six months we'd expect to see more announcements. So really like a query and own it, and it's a buy for us.
18:08
Andrew Gagan: A buy. Luke,
18:10
Unidentified speaker (UNKNOWN): would
18:10
Andrew Gagan: you concur?
18:11
Unidentified speaker (speaker_1): Yeah, look, I'll I'll say buy as well. Um I know this is one that Ben knows well. Um I've looked at it a few times in the past, and and to be honest, I think one of the only reasons I don't own this stock is I've I've got a fair bit of mining services exposure already. Um and so you know, you sort of don't want to have too much. to one sector. Uh but it it it sets up, you know, for the exact sort
18:31
Unidentified speaker (speaker_1): of uh investment scenario that I like to see, which is um as as Ben correctly pointed out, it's it's grown nicely over the last few years. Um it's got to that profitability inflection, um, plenty of cash in the bank, no issues there. And you've now won these big contracts that are due to to start coming online um from FY twenty seven and beyond. So that earnings growth. you
18:51
Unidentified speaker (speaker_1): know becomes a catalyst uh in in the future years. Um yeah, you know, looking forward, I think it's on about, you know, mid teens earnings multiple, but as I said, that's that's K garring, you know, quite strongly, as Ben pointed out. Um this this looks pretty good. He he knows it much better than I do from a you know pipeline projects point of view. I'm looking more just what's there today and
19:11
Unidentified speaker (speaker_1): and maybe six, twelve months out, but it all looks pretty good to me. I think this one that's it's a it's a buy as well.
19:16
Andrew Gagan: Alright, first double buy, that is Aquarian.
19:19
Andrew Gagan: Let's uh continue then with DMEM. It is the next stock. Alex asking about this. He does have a question, I'll get to that in just a moment. It is well it it's sort of essentially mining services uh and more essentially it's it's water treatment. And uh Alex saying we'd would love for the experts to review the company and currently hold a small part of
19:38
Unidentified speaker (UNKNOWN): the.
19:38
Andrew Gagan: parcel myself. I feel it's been unseen by the market, yet management has done a great job getting the business to an earnings inflection point. The company he says has many various accretive acquisitions over the last few years and has been able to extract value and growth momentum, leading into next financial year. Other small cap peers, he says, in the water treatment space have had their respective respected challenges. While Well the
19:58
Andrew Gagan: management of DMount appear to be delivering very well on business strategy, shout out to Luke for always. providing well-rounded and in-depth analysis. Long time listen, much appreciated. Thanks for the question, Alex. Um Luke, to the point, in fact, you own this, don't you do you
20:11
Unidentified speaker (UNKNOWN): not? I
20:12
Unidentified speaker (speaker_1): do. Yeah, no, I think he's talking about Luke Larative as well with that
20:15
Unidentified speaker (UNKNOWN): for that
20:16
Unidentified speaker (speaker_1): question.
20:16
Unidentified speaker (UNKNOWN): Okay. All right, we'll refer
20:17
Andrew Gagan: to Ben for that in
20:18
Unidentified speaker (UNKNOWN): a
20:18
Unidentified speaker (speaker_1): moment.
20:20
Unidentified speaker (speaker_1): Um no look this is this is one we own. I'll say I'll say it's a buyer. It was a small position for us as well, but we have added to it after the recent quarterly Um some parallels with Aquarium we're just talking about, both around that sort of 40-ish mil market cap, which has been pointed out, you can definitely fly under the radar from a micro cap market point of view. Um Alex is spot on. Like you look across the water services space
20:40
Unidentified speaker (speaker_1): and um Cydev, Fluence, even a Vaisan's had its issues in in recent months. Um I think sometimes you can pay for the sins of your peers and and the market can throw a whole sector in the bin without looking too close. closely at what's going on. But these guys are through that that inflection point as well, particularly on a cash basis where cash is a little better than the the the profit and loss statement for this
21:00
Unidentified speaker (speaker_1): business. Generated generated about a million bucks free cash flow so far um this year. They they run on a on a calendar year so uh through three quarters a mil. Fourth quarter is generally the strongest. I'm thinking that can be somewhere between one 1.5, point five two 2 mil for the full year. On that four 40 mil market cap, it starts to look pretty good. Now, I think one of the things you can poke a hole in is that most of
21:20
Unidentified speaker (speaker_1): the growth has been acquisitive. Um,
21:22
Unidentified speaker (UNKNOWN): but
21:22
Unidentified speaker (speaker_1): nonetheless, I still think they generate some decent organic growth. And I don't think you're paying too much for that, uh, particularly from from this point of view. So uh one we like, most of that sort of revenue and and cash receipts are recurring as well. They're not tied to these big lumpy projects like some of those peers. Uh Um so yes, one that was a small position for us, but we did add after the recent quarterly,
21:42
Unidentified speaker (speaker_1): which I thought was pretty strong. So definitely a buy for the program.
21:47
Andrew Gagan: Ben, um do you want it? Uh Luke referring to as actually your uh colleague, uh Luke. Uh maybe that was direct to that. Uh what do you what do you
21:56
Unidentified speaker (UNKNOWN): think? Yeah,
21:57
Unidentified speaker (speaker_2): I'm not sure. I think Winchester's being been a bit harsh on himself there, but I
22:00
Unidentified speaker (UNKNOWN): think
22:00
Unidentified speaker (speaker_2): Larative has uh is been familiar with this one from years gone by. But yeah, fr from what we can see, I mean this DMEM's been at this earnings inflection point uh since you know twenty eighteen, it feels like. Um yeah, I remember this one from sort of five years ago. They were talking about the same things, recurring revenue,
22:21
Unidentified speaker (speaker_2): uh decent contract pipeline, inflecting profitability. Uh but yeah, the reality is it's kind of struggled to really hit that uh that that cash flow positive territory. However, it kind of has hit that uh positive operating cash flow inflection in the last couple of quarters, uh did eight hundred and forty grand
22:41
Unidentified speaker (speaker_2): for the for the last quarter of operating cash flow,
22:43
Unidentified speaker (UNKNOWN): uh
22:44
Unidentified speaker (speaker_2): which is a bit of a step up from the June and March quarters. So if you kind of look at that on a uh in totality, it's probably trading on about 15, 20 times operating cash flow. Obviously you have to take a bid off for the off the bottom there for kind of lease and borrowing repayments and the like. So the feet the free cash flow multiple
23:04
Unidentified speaker (speaker_2): might be a little higher. But I just would question why why bother with this kind of um picking the bottom in a small business like this. when it's not like the economics are super attractive and scalable. So what I mean by that is these guys do the the build and operate, which they kind of say is a a
23:23
Unidentified speaker (speaker_2): capital light uh way to to do this water treatment rollout.
23:28
Unidentified speaker (UNKNOWN): Uh
23:28
Unidentified speaker (speaker_2): however, it does kind of require capital as well. Um, and these sorts of small businesses tend to be capital constrained. So versus say an Aquarian uh which has a bit more cash and uh and a and a a bit more debt capacity if they want to kind of scale up their growth, I
23:48
Unidentified speaker (speaker_2): don't see demembers being as high growth and as scalable. Um so yeah, it's probably not our preferred way. I mean, there's a little bit of director buying there, which is always a good signal.
23:59
Unidentified speaker (UNKNOWN): Uh
23:59
Unidentified speaker (speaker_2): and there's certainly uh a worse businesses out there, but yeah, it just kind of comes back to my point on Mo Show as well. It's like if you're not playing for that much upside, paying a fair price for a business with illiquidity risk, uh, it's just not the kind of investing that we try to do at Sandy Cru, I suppose.
24:16
Andrew Gagan: So no, hold, avoid.
24:20
Unidentified speaker (speaker_2): Sell, hold, avoid. Yeah, and pick your choice.
24:23
Andrew Gagan: All right. Uh two different opinions there on D DMEM. Mem. Um Ben saying not the worst stock. Well that's hardly a ringing endorsement, is it? All right.
24:33
Andrew Gagan: Let's now move to because Luke begs to differ. Um let's uh move to our task. Our next stock. It uh is look I mean this is the uh the online marketplace um for uh well getting a handyman essentially, uh people to businesses, uh work done around the house and so on. And um just looking at
24:53
Andrew Gagan: its um last result then um it's fairly strong in fact a trading update there in uh mid-October. Uh Ben, what do you
25:02
Unidentified speaker (UNKNOWN): think?
25:04
Unidentified speaker (UNKNOWN): Yeah
25:04
Unidentified speaker (speaker_2): it's an interesting business. Um at risk of sounding kind of too sceptical, I suppose what's the best business in the world? Uh in our view it's it's recurring revenue. You make
25:14
Unidentified speaker (UNKNOWN): uh one
25:14
Unidentified speaker (speaker_2): sale to a customer and then you can continue to bill them in perpetuity. So I think people have kind of forgotten that amidst the SAS pocalypse where software businesses have have fallen out of favor uh with AI potential threats, but
25:27
Unidentified speaker (UNKNOWN): the
25:28
Unidentified speaker (speaker_2): recurring revenue is still a good business model regardless of the industry.
25:31
Unidentified speaker (UNKNOWN): Uh
25:32
Unidentified speaker (speaker_2): unfortunately, that's not really Airtasker's business model. So I sort of lump Airtasker in with with high pages, which is another uh small cap marketplace stock, where they're just more lead generations uh platforms rather than a recurring revenue platform. So High Pages is another it's been it's
25:52
Unidentified speaker (speaker_2): been struggling with the same thing. They try to introduce subscription to keep to make it stickier uh and provide benefits associated with that. But the reality is if if you've ever used Airtasker, you just use it
26:02
Unidentified speaker (UNKNOWN): you use
26:02
Unidentified speaker (speaker_2): it once, find your um preferred
26:06
Unidentified speaker (UNKNOWN): uh
26:06
Unidentified speaker (speaker_2): tasker, I think they call them,
26:08
Unidentified speaker (UNKNOWN): uh,
26:08
Unidentified speaker (speaker_2): to do your job around the house and then you just sk skirt the platform. Uh and you know I'm not speaking from experience there, just in case they're uh they're listening, but I think that's just the more broader theme that that happens with this business. So it's kind of hit decent scale in Australia. Um but you've still gotta got pay to your marketing
26:28
Unidentified speaker (speaker_2): costs uh and your customer support and your overheads with all that potential churn risk. So I think the Australian business is decent and everything has a price, uh certainly. So yeah, that's kind of more mature growing at about 15%. And then you've got these offshore businesses uh where they're trying to roll out the same model, it's a bit higher growth, uh, but
26:48
Unidentified speaker (speaker_2): they're more sort of cool options at this stage. Unfortunately, don't love the fact that they're kind of issuing equity in these media partnership deals uh to kind of grow from a from a marketing distribution perspective. Um so you're getting diluted. But yeah, on the surface the stock's kind of cheap, but yeah, just don't really love the business model. So no
27:07
Unidentified speaker (speaker_2): need to to rush in. Um I'll say if you if you know it really well, you've got high conviction in those things, it's maybe a hold rating, but yeah, another one that's probably not for us. So we'd say a sell.
27:17
Unidentified speaker (UNKNOWN): Um
27:18
Andrew Gagan: okay, a hold or a sell depending on your circumstances there. Um so Luke um has seen some record marketplace activity there, uh gross marketplace volume surging uh more than twenty percent year on year. But to Ben's point, I mean, is it a flawed model? You you know, you find your task, tasker
27:37
Andrew Gagan: and that's it. Why do use them again?
27:40
Unidentified speaker (UNKNOWN): Yeah,
27:41
Unidentified speaker (speaker_1): look, it's certainly a big problem they have with the the platform, and they talk about that every you know earnings call you dial into. Um I think Ben summarized this pretty well. The the the Aussie business looks pretty good. And and to be honest, if you told me I was just buying the Australian business, I could certainly make a case for the share price, you know, being a good chunk higher than where it is today. Um
28:01
Unidentified speaker (speaker_1): the problem is, oh well, you know. problem's not the right word because there's a you know uh upsides to this, but um uh all of the profitability and cash flow from the Australian business is being spent on international expansion.
28:12
Unidentified speaker (UNKNOWN): And
28:12
Unidentified speaker (speaker_1): I think it's creating a very sort of difficult investment thesis for the market. And it's not a very easy business to understand, particularly if you you know are someone who you know tries to focus on the accounts. Um there's a lot of non-cash um uh charges to this business. because of those media equity media equity deals that Ben was referring to. The valuation of them
28:32
Unidentified speaker (speaker_1): changes period to period. So you get these big swings in the PL. Um and also you're you're taking a lot of your cash costs and sort of funneling it through you know future equity obligations, which is it's quite complicated to try and get your head around. Well, what am I actually paying for this business today, trying to factor in future dilution? The big problem I have though, and this is one I've had on my watch list for quite a while, because it can
28:51
Unidentified speaker (speaker_1): be a business that works at scale, um, is the UK looks okay, and I think there's a chance the UK could turn into a a good little segment for this business.
29:01
Unidentified speaker (UNKNOWN): The
29:01
Unidentified speaker (speaker_1): US looks pretty cooked, to be honest. Um, they were doing uh you know 100% plus year on year growth, 160% was was one of the quarters last year. That growth rate fell to twenty seven percent in the first quarter, twenty twenty-seven. seven. That's just nowhere near enough. for what's being spent. Um, I know it can be lumpy quarter to quarter and and sort of, you know, advertising can be targeted to different
29:21
Unidentified speaker (speaker_1): bits and pieces. But to be honest, I mean, I I would keep this one on your watch list if you're not there. Um, maybe a hold if you are there with conviction, but the big catalyst for me with this stock would be some sort of strategic review of the business where management came to some sort of arrangement where they're backing out of the US uh and sort of focusing their efforts and sort of
29:41
Unidentified speaker (speaker_1): returning capital back to shareholders from an Australian point of view, which is much more mature, as Ben pointed out. So
29:46
Unidentified speaker (UNKNOWN): tough
29:46
Unidentified speaker (speaker_1): one, Andrew. I'll say I'll say a hold. Um, but this is one that I think if they keep throwing money at the US, I think the share price just keeps dwindling lower and lower.
29:54
Andrew Gagan: All right. Okay. A hold and um Ben been more likely to sell. Let's uh turn to the next stock. It is a ANOVA Nova I Medical. Now, in fact. this is Luke's pick, so um let's go there. It um is um essentially uh look it's uh it's a biotech um manufactured sells um ophthalmalic um
30:14
Andrew Gagan: treatment um obviously used by eye surgeons uh around the globe in fact. Uh Luke, why have you chosen this?
30:24
Unidentified speaker (speaker_1): I've got a pretty similar thesis to DMEM here Andrew so I'm a bit nervous about what Ben's going to say. Um but this is around that sort of 40, you know, uh 45 mil market cap, um, hitting through that sort of inflection point for cash flow and profitability. Um, you know, it's a business med tech and biotech's a very tricky segment. Um, but I
30:44
Unidentified speaker (speaker_1): think one of the things we look for as investors, particularly on the ASX, are these businesses that can start to get towards commercial scale, particularly in the US. You know, you see businesses who sometimes carve out and market in Australia, in Europe. They're very tough markets for these businesses, but the US is the lucrative market. And if you're able to
31:04
Unidentified speaker (speaker_1): carve out a space in the US, you can do quite well. But look, it's a business that's grown its revenue about 25-30% 25, 30 percent over the last four or five years. Now, rewind. four or five years ago, that was coming off a pretty low base, and and you know, you sort of had to keep doing that to sort of hit the scale. We're now at the point where you know they're creeping up towards 30 mil
31:23
Unidentified speaker (speaker_1): USD, 40 mil AUD, still growing at those sorts of rates, potentially even accelerating if you look at sort of the last quarterly and the commentary from management at the AGM about October. Um, and so you know, 70% gross margins, um, opex. that has been growing modestly over the last few years, but relatively steady compared to revenue, um,
31:44
Unidentified speaker (speaker_1): you can start to model out where the profitability of this business starts to come through. So the big risk here though, of course, balance sheet still a question mark. There's a bit of cash in the bank, but if you did get a slowdown in that that um sales and that revenue growth rate, it would hit that that profitability, hit that cash, and all of a sudden the balance sheet becomes at risk. But I think you're sort of one or two. quarters away of this
32:03
Unidentified speaker (speaker_1): compound growth continuing, as I said, which it has for quite a while, from seeing a business that's that's quite profitable and I think should start catching the eye of the market around that sort of one time sales, which is a bit cheap for um a business that's starting to commercialize and scale up, particularly in that US market. So a bit like the MEMP, we had a very small position in this one, you know, going back uh about nine, nine,
32:24
Unidentified speaker (speaker_1): ten months ago, but after the last recent quarterly, added some more. I thought that was one that
32:27
Unidentified speaker (UNKNOWN): sort
32:28
Unidentified speaker (speaker_1): of showed that thesis still very much on track.
32:30
Andrew Gagan: All right, calling out a buy then. Um
32:32
Unidentified speaker (UNKNOWN): Ben,
32:33
Andrew Gagan: are you convinced?
32:36
Unidentified speaker (speaker_2): I think again, I would say Luke knows this one well. I think he's given it a good overview there. I suppose there's a lot of these inflecting profitability stories out there on the ASX, particularly in this
32:46
Unidentified speaker (UNKNOWN): sort
32:47
Unidentified speaker (speaker_2): of sub sub-50 50 mil market cap range where
32:49
Unidentified speaker (UNKNOWN): pretty much
32:50
Unidentified speaker (speaker_2): every company in that range which is either loss-making or borderline profitable needs to convince the market that it's hitting that inflection. So they talk to the brokers, they talk to investors, and that's the story they're selling. So I s I think you've got to be pretty um, I suppose take it with a grain of salt and do your own work on what you think it's gonna do
33:10
Unidentified speaker (speaker_2): or what it's worth. So yeah, I remember this business from a few years ago. It was a
33:14
Unidentified speaker (UNKNOWN): uh
33:15
Unidentified speaker (speaker_2): when I was actually working at Evanson Partners and they covered the stock uh and they were quite bullish on it. That might have been twenty twenty one or so. Um and yeah it kind of hasn't delivered so colour me unconvinced at this point, Andrew, I think they're doing all the right things at the moment. Like haven't looked at it in a l little a little
33:35
Unidentified speaker (speaker_2): while and I will say it's kind of impressive when you look at the the quarterly
33:39
Unidentified speaker (speaker_2): Uh, they're still pretty low market share, they've got good growth, so it looks like they're kind of kicking goals there, but it is still small. So if they lose uh a bit of traction, even in just sort of some some small a small number of sites, uh, that revenue and earnings can pretty quickly go backwards. That's probably one word of
33:59
Unidentified speaker (speaker_2): warning I would say. Uh, and another one is just in terms of this. med tech
34:05
Unidentified speaker (speaker_2): space, there's a lot of small uh wannabes, I suppose. And I would just question what's the edge uh for any given small med tech company versus the large players. So there's a lot of really big, particularly the US-based ones, uh really cashed up, big budgets to throw at RD for these kind
34:25
Unidentified speaker (speaker_2): of things. Um
34:27
Unidentified speaker (speaker_2): Saluda was uh a medtech IPO on the ASX recently which on paper looked pretty pretty reasonable. Uh good product, good growth. Share price just been smashed. Uh they they do face some competition. As soon as they have a little stumble in terms of operational issue or or product recall uh the market just kind of loses confidence.
34:47
Unidentified speaker (speaker_2): So
34:47
Unidentified speaker (UNKNOWN): yeah
34:47
Unidentified speaker (speaker_2): fair bit of risk in this one still uh and and the final point is just liquidity. So
34:53
Unidentified speaker (UNKNOWN): uh
34:53
Unidentified speaker (speaker_2): at the end of September I think they've got four mil of liquidity, but that's actually two of cash and two of debt, I believe. So pretty skinny in terms of funding uh from from our perspective. So potentially you get to look at this one in a capital raise at a discount. So that's the other thing I'd be uh be thinking. So look it looks okay here. Uh I'll call it a hold for the program, programme, but yeah
35:13
Unidentified speaker (speaker_2): not one where sort we're of super keen on and and not one we own.
35:17
Unidentified speaker (UNKNOWN): Let's
35:17
Andrew Gagan: sum up the first half then, beginning with Mercio is under that takeover offer. Uh Luke um s has already sold a bit, he owns it, um so it's a hold, whereas um well Ben's saying it's sort of subscale for him so he would sell it. Uh Aquarian, it is a buy from both. That is a double buy uh one to consider there. Um Ben owns it, uh sees it as cheap.
35:37
Andrew Gagan: Uh Luke's seeing some good growth there in terms of its contract pipeline. DMEN, Luke owns it and uh would buy it still. Whereas Ben has a very different opinion. He would sell it. Um, just so sees it as being capital constrained. Airtasca, it is a sell from Ben.
35:55
Unidentified speaker (UNKNOWN): Uh
35:56
Andrew Gagan: Luke more likely to hold it. Um, both uh well, this it's sort of they're wary of the international expansion, particularly the risks in. the US, which um Luke says is not really working for them. And finally, the Nova I Medical, which was Luke's pick, so he is buying it, whereas um
36:11
Unidentified speaker (UNKNOWN): Ben
36:12
Andrew Gagan: more likely to hold
36:13
Unidentified speaker (UNKNOWN): it.
36:15
Unidentified speaker (UNKNOWN): All
36:15
Andrew Gagan: right, catching up with our own high conviction fund picked by the investment committee. Now the latest one has just landed at osbiz.com.au. So going into November, the panel exited a key holding and increased its exposure to a stock that has. had a difficult October. We're not going to give it away. You'll need to go to the website, look for that drop-down menu, the investment committee, uh, and you
36:35
Andrew Gagan: get the explanation as to why they make those changes. And of course, that's all based on your request. So keep them coming in.
36:46
Unidentified speaker (UNKNOWN): The
36:46
Unidentified speaker (speaker_1): shopper in me though does foresee potentially some bargains out there.
36:51
Andrew Gagan: Investors will have a bit more cash to deploy.
36:54
Unidentified speaker (speaker_3): Live wek days from 4 p.m. Eastern, watch on demand or catch up with the newsletter or podcast. The COB is brought to you by Longview, a new way for investors to access Australian residential property. Visit longview.com.au.
37:12
Andrew Gagan: Next five, we're going to take a look at Healthco. Healthcare and Wellness REIT, ReadyTech, SIG Global, Motorcycle Holdings, and Propel Funeral Partners. So let's get into it then. This is in fact Ben's pick. Healthco Healthcare and Wellness REIT.
37:27
Andrew Gagan: And so this is obviously a real estate investment trust. Ions Managers develops health and wellness assets across the country. Ben, why have you chosen
37:37
Unidentified speaker (UNKNOWN): it?
37:39
Unidentified speaker (speaker_2): Yeah, Andrew, I've talked about sort of the plethora of other opportunities that I'd rather buy. This is one of them. Healthco, it had a an issue where it's anchor tenant. So they own a bunch of hospitals essentially, or healthcare clinics. Uh it's a real estate investment trust. Uh and yeah, it's its it anchor tenant was
37:58
Unidentified speaker (speaker_2): Healthscope. Health Scope. So people may recall Healthscope because it was in administration.
38:03
Unidentified speaker (UNKNOWN): Uh
38:04
Unidentified speaker (speaker_2): was going through a process where, you know, they were trying to get a a buyout, they were trying to recover
38:10
Unidentified speaker (UNKNOWN): the
38:11
Unidentified speaker (speaker_2): the debt which the private equity guys all bought up. And yeah, it was just a bit messy. So there was a lack of certainty for for Health Co. Uh and they paused distributions. So REIT rate investors never seemed to like that. Uh and the shares traded down. So what's what makes this interest really interesting to us is we formed a view
38:30
Unidentified speaker (UNKNOWN): uh
38:30
Unidentified speaker (speaker_2): probably earlier in the year, I'm not sure, maybe mid mid this year, that the health scope issues were going to be resolved one way or another. Uh either a sale or and a new operator would take on the leases or they would re-tenant the hospitals uh because they'd had they'd That lined up um I suppose backup tenants that were willing to take on take over those leases.
38:51
Unidentified speaker (speaker_2): with a a a small rental incentive. So
38:54
Unidentified speaker (UNKNOWN): yeah,
38:54
Unidentified speaker (speaker_2): we we looked at the situation, thought they were going to resolve it. Sure enough, they've done that, they've gone and executed a bunch of uh binding agreements. Healthscope is now, as far as we're concerned, resolved.
39:05
Unidentified speaker (UNKNOWN): Uh,
39:05
Unidentified speaker (speaker_2): and that removes a major overhang on the stock. HCW HEW has said that they are going to reinstate distributions, uh, was doing six cents per. unit. So annualized, you can you can do the numbers on that. It's about an eight percent dividend yield. Uh and despite this resolution,
39:23
Unidentified speaker (UNKNOWN): the
39:23
Unidentified speaker (speaker_2): shares trade at a huge discount to NTA. So NTA
39:27
Unidentified speaker (UNKNOWN): uh
39:27
Unidentified speaker (speaker_2): the net asset value is a dollar thirty-five as at thirty June,
39:31
Unidentified speaker (UNKNOWN): which
39:31
Unidentified speaker (speaker_2): we think is probably conservative because they've taken a bit of a haircut on that just on uh higher interest rates. You you you adjust your capital. cap cap rate and also uh a bit of uncertainty with this hellscope thing. So shares are trading at 75, 76 cents, uh trades at a 48% discount to book value. We saw another REIT,
39:51
Unidentified speaker (speaker_2): ARF is the code, that re-rated forty-two percent once it resolved its child care tenant issue um
39:59
Unidentified speaker (UNKNOWN): in
40:00
Unidentified speaker (speaker_2): the you know the last few months. So we think that's kind of the analog. analogue here. See HGW is having quite conservative gearing, so scope for further potential dividends. Um and yeah, I think REITs as a sector look really interesting for the first time in a long while. So if we think uh rates have peaked, which the narrative from
40:20
Unidentified speaker (speaker_2): the RBA and I suppose the bond market pricing suggests we may have, uh a lot of these REITs trading at 30% plus discounts to to NTA look pretty interesting. Uh they've they're generating good yields. They've they're, you know, they're high quality properties with with replacement values far in excess of their
40:39
Unidentified speaker (speaker_2): NTA reported in the financials. And yeah, so really like HGW here. I think it's a say um a table banger. So it's one we own uh
40:48
Unidentified speaker (UNKNOWN): quite a
40:48
Unidentified speaker (speaker_2): few shares of in our Seneca Australian Small Companies Fund. Yep. As well as we actually own the head stock HMC, which if HGW goes well, the the head fund manager stock that manages the REIT should also perform well. So
41:00
Unidentified speaker (UNKNOWN): yeah,
41:00
Unidentified speaker (speaker_2): eight percent plus dividend yield, huge discount to NTA. I think that's kind of one of these other opportunities in the market. So we'll call it a buy.
41:07
Andrew Gagan: All right. A a table thumping Something by uh no less Luke, is that what you're doing or not?
41:14
Unidentified speaker (UNKNOWN): Um
41:14
Unidentified speaker (speaker_1): I'll say a bye. I'd I'd I wouldn't say table thumping. It's at the end of it it is a REIT at the end of the day, right? Like um no look, I agree with all that. It's not one I've kept up with. Obviously, you know, articles in the AFR and everything like that, and in particular the media likes to stick the boot in a bit of tall poppy syndrome around HMC and David DePilla. So there was a lot of
41:34
Unidentified speaker (speaker_1): reporting on it, and I I you know, again, being a bit larger cap and being a REIT, um not something I'm looking at every day. But looking for the program on on Ben's suggestion, um, yeah, I see the fees as pretty cleanly here. Um you've got obviously that discount to NTA, even if you're not a big believer in what that NTA might be on paper, you know, you're getting a distribution yield around eight percent. Now for, you
41:54
Unidentified speaker (speaker_1): know, um prime hospital assets, you look across some of the other um, you know, uh specialized REITs, depending on what sort of sectors they're in, obviously office and and some things like that you can officer sometimes see higher yields but generally, you know, maybe a six percent yield, something in in that sort of range. So I can see I can see upside here of of twenty-five, you know, maybe forty
42:14
Unidentified speaker (speaker_1): percent of the market gets really excited, um and you're underpinned by a good yield. So
42:19
Unidentified speaker (UNKNOWN): not
42:19
Unidentified speaker (speaker_1): the sort of stock I'm chasing, you know, as we We've sort of discovered on this program. Um I'm a bit more down the risk spectrum with with some of this stuff, but yeah for some someone you know looking for for this sort of opportunity, get a good income and and then potentially you know the upside of um some capital gains as well as the business starts to to improve. I like this one as well. So bye.
42:38
Andrew Gagan: Double bye then. Rideo. That's uh Healthco and Healthcare Wellness REIT. Uh gentlemen, we're better pick up the pace. Uh let's turn to ReadyTech. It is the next stock. Uh Jason asked about this, is a SaaS provider. essentially with um in the education, employment, workforce, management, and also government sectors, which is clearly a positive.
42:58
Andrew Gagan: Luke, what do you
42:59
Unidentified speaker (UNKNOWN): think?
43:00
Unidentified speaker (UNKNOWN): Uh
43:00
Unidentified speaker (speaker_1): look, I don't mind this one. They had a bid at two bucks um not too long ago. I think there was some some um contingencies to that. I think it was a dollar seventy five for for minimum acceptances and things like that. But uh not not sure how serious the bid was, but but that was the number that we. was thrown out. And look, to be brutally honest, I I I think management should take that. Um it to
43:20
Unidentified speaker (speaker_1): the business here today though, at you know, dollar thirty ish price, um, one point five times ARR, about eleven times cash e but dah, that screens pretty good. I uh my main point though for this business, I sort of land on is I I think this business is closer to an Iris or a Hansen than it is to a tech one or a Wise WiseTech. Tech. And I think management, maybe
43:40
Unidentified speaker (speaker_1): investors as well, you know, that have been holding on from higher levels for I think it got up to $4.50, maybe five bucks at one point. You know, maybe thinking this business deserves a five, six times ARR multiple. I I think structurally those days are behind us. I think two to three times ARR is now just the number for these more mature software businesses. They still have all the
44:00
Unidentified speaker (speaker_1): same good economic characteristics Ben was highlighting before. So, you know, um they are better than your average business, but there's genuine structural threats to them from AI and they have to really be nimble over the next few years. Um I I think that two dollars was, you know, from what I could see would have been pretty good where we are today. I think it's a it's it's it's a buy, it's definitely a hold. Um
44:20
Unidentified speaker (UNKNOWN): but
44:20
Unidentified speaker (speaker_1): I think you know, if you've got a border management team, you know, trying to turn this one back into a high growth software, I'd be a bit skeptical. sceptical. I I'd like to see them become, you know, sort of accept the mature business, look for more distributions back to shareholders, dividends, capital returns, buybacks, things like that. So
44:35
Unidentified speaker (UNKNOWN): I thought
44:35
Unidentified speaker (speaker_1): I s I flip flopped a lot there, Andrew. I'll say buy. Oh,
44:39
Unidentified speaker (UNKNOWN): not a table not
44:40
Unidentified speaker (speaker_1): a not a okay, not a table thump. Not a table thump.
44:43
Andrew Gagan: All right. Uh Ben, what do you
44:45
Unidentified speaker (UNKNOWN): think?
44:47
Unidentified speaker (UNKNOWN): Uh
44:47
Unidentified speaker (speaker_2): yeah, pretty much agree. It's been a frustrating one, Ready ReadyTech. Tech. Uh they've
44:51
Unidentified speaker (UNKNOWN): yeah,
44:51
Unidentified speaker (speaker_2): as Luke said, knocked back a a a bit at let's call it two dollars cash, shares trading at a dollar thirty. Uh and that's after they had a deal in November twenty twenty two from another private equity group offering four dollars fifty cash, which uh ended up falling over. But I think yeah, there's a bit of a track record of kind of
45:11
Unidentified speaker (speaker_2): operational disappointment beginning to form here. Uh and so just despite the stock looking cheap, it's got pretty resilient contracts in the you know the the lower level government and education spaces.
45:22
Unidentified speaker (UNKNOWN): Uh
45:23
Unidentified speaker (speaker_2): so it's sort of trying to position itself as a mini tech one. But yeah as Luke said it hasn't really lived up to that reputation. So yeah been disappointing. Um
45:32
Unidentified speaker (speaker_2): we've actually owned it before but uh don't own it now. So I suppose that kind of tells you what our view is here. I think yeah, the the market's sort of telling you as well. So bit of a disappointing one. Um
45:45
Unidentified speaker (UNKNOWN): I think
45:46
Unidentified speaker (speaker_2): there's better opportunities in the software space. I think ReadyTech's cheap, but just doesn't catch a bid. Like you look at yesterday
45:51
Unidentified speaker (UNKNOWN): uh
45:51
Unidentified speaker (speaker_2): when when the software businesses, I think the software index on the ASX was up almost about 10%. Uh, and sure enough, ReadyTech flat with basically no trades. So
46:01
Unidentified speaker (UNKNOWN): yeah,
46:01
Unidentified speaker (speaker_2): I think if you're if you're sneaking. sniffing around the software space, you're probably better in these larger uh high quality names. We like a few of them. I'll rattle off a few of them. Uh Catapult, SiteMinder, Zero, and Aura, AXQ. Uh yeah, which trade on also pretty cheap valuations
46:21
Unidentified speaker (speaker_2): relative to their quality and growth prospects. Uh and yeah, just have a bit more upside. potential, I suppose.
46:28
Andrew Gagan: Alright. So what, sell it to buy those?
46:31
Unidentified speaker (UNKNOWN): Yeah.
46:31
Andrew Gagan: Yeah. Okay. All right. Well, another difference of opinion there. We're buying a sell for RETEC. Let's uh turn to SRG Global, back in that sort of services space, in particular, construction engineering, and um has had some uh recent operational financial milestones uh with uh contract we're
46:50
Unidentified speaker (UNKNOWN): gonna.
46:50
Andrew Gagan: wins. Ben, how do you see?
46:54
Unidentified speaker (UNKNOWN): Yeah,
46:55
Unidentified speaker (speaker_2): decent business. Um, I think we've seen recently the contractors rolling off a bit. SRG is one that still trades on 21 times earnings. Now, contractors typically you buy them on 10 times, you sell them on 15 times. Uh they inevitably have a bad contract,
47:11
Unidentified speaker (UNKNOWN): you know,
47:12
Unidentified speaker (speaker_2): fixed pricing or whatever it may be, cost overruns. they they lose money on it, and then the market reprices them down to sort of sub ten times earnings.
47:20
Unidentified speaker (speaker_2): SRG is probably one of the better ones, got a good track record, uh, more recurring revenue, more sort of diversified infrastructure, mining services, uh type contracts, if I'm not mistaken, versus a lot of these electrical contractors, which are more pure players.
47:36
Unidentified speaker (UNKNOWN): Uh,
47:36
Unidentified speaker (speaker_2): I think your you're sort of Southern Cross, your Genius, your SD. SKS. So
47:40
Unidentified speaker (UNKNOWN): yeah,
47:41
Unidentified speaker (speaker_2): it's okay, it's a decent business.
47:46
Unidentified speaker (speaker_2): But I was just reminded the other day by an email from a broking group which was hosting an electrical contractor conference. So
47:54
Unidentified speaker (UNKNOWN): that
47:54
Unidentified speaker (speaker_2): to me tells me we're at or near the top of the cycle. I recall seeing similar conference invites for you know oil and gas over the last few. months. Before that it was copper, lithium, gold. Each time kind of marked peak euphoria in the sector. Uh I actually wrote an article which kind of s suggested that there might be a bubble in
48:13
Unidentified speaker (speaker_2): contractors
48:14
Unidentified speaker (UNKNOWN): uh
48:15
Unidentified speaker (speaker_2): a few months ago and just on the basis that a lot of them were trading on twenty five thirty times earnings. So Mm-hmm. yeah, you just don't make money unless there's really sustained growth with no mess ups, which just just doesn't happen in this space. So SRG is just a bit expensive for us in summary. Uh and
48:32
Unidentified speaker (UNKNOWN): yeah,
48:33
Unidentified speaker (speaker_2): I've highlighted Aquarian is probably one that we prefer.
48:36
Andrew Gagan: Yep.
48:36
Unidentified speaker (speaker_2): Even the electrical guys, like SKS has pulled back a fair way in recent times and is probably another one that's probably more interesting than SRG from our perspective.
48:44
Andrew Gagan: Alright, so once again selling it to buy those.
48:47
Unidentified speaker (speaker_2): Yep.
48:47
Andrew Gagan: Yep. Okay. Luke?
48:50
Unidentified speaker (UNKNOWN): Yeah I'll be
48:50
Unidentified speaker (speaker_1): quick. in the interest of time here, Andrew. I agree with everything there. I had Tasmia on the program a couple of weeks ago and said almost the exact same thing. Um these are like good businesses relative to um, you know, maybe peers in the sector or uh historically, you know, you know, seeing some really good results. But I think investors are a bit like the frog in the boiling water here with the
49:10
Unidentified speaker (speaker_1): valuations of these contractors, and Ben's completely spot on. Inevitably we'll see. one of them have a contract go bad, a slowdown, whatever the issue might be, and we'll get a reminder of why you try not to pay more than you know 15 times earnings for these sorts of businesses. So I said for Tasmia back then, definitely take profits. If you wanted to make the argument to me, you know, they're good businesses and I
49:30
Unidentified speaker (speaker_1): want to hold some of it, I I can be fine with that. But if you've held any of these contractors, Tasmia, Monodelphus, SRG, NRW, you
49:37
Unidentified speaker (UNKNOWN): know,
49:37
Unidentified speaker (speaker_1): they're all their charts. look exactly like what like what we've just put up. Um I probably wouldn't go as far to say bubble as Ben did, but certainly this has been a crowded trade for quite a while. You you're taking profits in these names here. Um it's just it's it's hard to make money long term paying these sorts of multiples and expecting the ongoing operational excellence that they've all had to keep continuing. So um yeah, we'll
49:57
Unidentified speaker (speaker_1): say a sell, but they are good businesses, I'll get I'll grant them
50:00
Unidentified speaker (UNKNOWN): that good
50:01
Andrew Gagan: businesses, but it is a double sell for SIG Global.
50:04
Unidentified speaker (speaker_1): Everything has a price.
50:06
Andrew Gagan: Let's turn to motorcycle hauling's the next stock. Alex asking about this. It is the distributor of um motorbikes also uh parts and accessories. And uh did log record sales revenue uh at its past results there. Luke.
50:21
Unidentified speaker (UNKNOWN): Oh
50:21
Andrew Gagan: actually before we get to that, let Alex has a question saying could I ask the experts for a view regarding the stock? business prospects and earnings stability.
50:31
Unidentified speaker (UNKNOWN): Yeah,
50:31
Unidentified speaker (speaker_1): look, had this one come up a few times and every time I look at it I have the same view, which is this is a better business than than probably I think what the market realizes and certainly what the valuation um sort of uh displays as well. Um AP Eagers is held up as, you know, uh the that the best car retailer in the country. They have about a twenty 20% percent market share of new cars in Australia. That's what these
50:51
Unidentified speaker (speaker_1): guys have for motorbikes. You
50:53
Unidentified speaker (UNKNOWN): know,
50:53
Unidentified speaker (speaker_1): they are a dominant player in the space. Um you're able to see that in their sort of economics, their margin profile, and sort of their sustained uh returns on capital. Um, but nonetheless, the problem you have, and uh the AP Eagles comparison works because it's had similar similar problems, is highly discretionary businesses. And so um despite trading on eight times
51:13
Unidentified speaker (speaker_1): earnings, the difficulty for me here with motorcycle holdings, management's already flagging some of these pressures, you know, on the consumer, um, on households moving forward, um, you know, what does that start to look like for earnings into FY27 and beyond? So again, a bit like SRG, if you said to me, I like this business longer term, management, the positioning, I want to hold it, I'm I'm not gonna sell someone when you
51:33
Unidentified speaker (speaker_1): have to sell your shares, but um be just be aware that that multiple, you know, there's there's two parts to it. There's the P, but there's also the E. And and what the what the earnings do from here, that multiple could very quickly move given the leverage in these businesses. So I'll say a hold, Andrew, but nervous, nervous hold.
51:51
Andrew Gagan: Okay.
51:52
Unidentified speaker (UNKNOWN): Ben?
51:54
Unidentified speaker (UNKNOWN): Yeah,
51:54
Unidentified speaker (speaker_2): I'll also give it a hold. I think it's a pretty interesting business, as Luke mentioned, it's probably
52:01
Unidentified speaker (UNKNOWN): got
52:01
Unidentified speaker (speaker_2): a bit of a quality re re-rate rate potential in it, uh, just in terms of how they're distributing motorcycles. But
52:07
Unidentified speaker (UNKNOWN): yeah,
52:08
Unidentified speaker (speaker_2): I just see better opportunities again. I think um AP Egers was mentioned there, uh that trades on a pretty high valuation. But one in the in the auto dealer space, which is cheaper than both motorcycle and AP Eagles, is Auto Sports Group, ASG, which has come down a long way. Uh trades on about five times earnings
52:28
Unidentified speaker (speaker_2): versus motorcycle on about eight times. I actually think ASG has some really good earnings growth potential here. So they've kind of broken into this luxury EV uh and luxury uh you know, petrol car markets and have a really dominant position in those in those markets. And yeah, huge backlog of orders at the moment, particularly on the E EV V
52:48
Unidentified speaker (speaker_2): side,
52:48
Unidentified speaker (UNKNOWN): uh
52:49
Unidentified speaker (speaker_2): in in pretty good locations. So yeah, they're kind of continuing to be acquisitive, continuing to pay out good dividends, founder led,
52:55
Unidentified speaker (UNKNOWN): uh,
52:56
Unidentified speaker (speaker_2): and wouldn't be surprised if that re-rates significantly or could even be a buyout candidate itself with with the multiple discrepancy between ASG and peers. So
53:04
Unidentified speaker (UNKNOWN): yeah,
53:05
Unidentified speaker (speaker_2): don't mind the space. This is actually probably a space where we're more positive on the the retail, the consumer discretionary,
53:10
Unidentified speaker (UNKNOWN): uh
53:11
Unidentified speaker (speaker_2): counterintuitively as the environment has kind of gotten worse to the point of we think. it's probably bottomed here from a uh an economy in a rate cycle perspective. So yeah, I'll go a hold as well, but uh I would prefer ASG.
53:25
Andrew Gagan: Okay.
53:26
Unidentified speaker (UNKNOWN): Uh
53:26
Andrew Gagan: that's a hold and a nervous hold uh for motorcycle holdings. Finally, let's um turn to the business of death. in It is his propel funeral partners, and it's uh what well, in fact, I think it's the second largest provider of uh so-called death care services, uh
53:44
Unidentified speaker (UNKNOWN): in
53:44
Andrew Gagan: uh obviously in terms of uh funerals and the accompanying services that they uh provide. And in fact, Jared has brought this to our attention saying, not the most uplifting business model to think about. Well, you're right. Um
53:57
Andrew Gagan: so uh he's saying demographics are tailwind, yet margins are lower than I would have expected. expected. Ben,
54:05
Unidentified speaker (UNKNOWN): what
54:05
Andrew Gagan: do you think about
54:06
Unidentified speaker (UNKNOWN): it?
54:07
Unidentified speaker (speaker_2): Yeah, agree, it's not the most uplifting business model. It's probably not the most exciting stock either. It's been pretty pretty low growth for a while. So I
54:16
Unidentified speaker (UNKNOWN): think
54:16
Unidentified speaker (speaker_2): they're growing top line at 1%.
54:20
Unidentified speaker (speaker_2): Uh and yeah, second largest provider, Invocare was taken off the boards by private equity. They got a decent premium from that.
54:29
Unidentified speaker (UNKNOWN): Uh,
54:29
Unidentified speaker (speaker_2): and I think the view there was that they had all these prime real estate locations and they were gonna spin off the real estate in in the old sale and lease back model, which would free
54:38
Unidentified speaker (UNKNOWN): up uh
54:39
Unidentified speaker (speaker_2): a lot of capital and and make the effective purchase price a lot cheaper. So that's kind of the playbook. I think Propel is also has some some decent locations, but it's more tier two.
54:51
Unidentified speaker (UNKNOWN): uh,
54:52
Unidentified speaker (speaker_2): I believe. So a bit more regional and lower market share than in Bicare. So
54:57
Unidentified speaker (UNKNOWN): yeah,
54:58
Unidentified speaker (speaker_2): it's probably not the kind of the leader here.
55:01
Unidentified speaker (UNKNOWN): Uh
55:02
Unidentified speaker (speaker_2): it does have a lot of debt, so it's kind of creeping up above that three times net debt to EBITDA. Um company continues to to pay out dividends and and has made a lot of acquisitions, so it sort of makes. me nervous there on the leverage like that's the kind of thing that you can sort of unforeseeably blow up on. Um
55:22
Unidentified speaker (UNKNOWN): and
55:22
Unidentified speaker (speaker_2): yeah I think they've been blaming this seasonal or cyclical weakness in the the number of deaths for the last few periods now to the point where I'm sort of starting to look at that and think could these issues be more structural uh and that they're maybe losing market share.
55:36
Unidentified speaker (UNKNOWN): Uh
55:37
Unidentified speaker (speaker_2): I'm not too sure. I think it's trading on about 17 times earnings, which is about as low as it's ever traded. Dividend yield now above 5% for the first time. So on a valuation basis, looks okay, but you just want to see a bit more confidence that they are back on the earnings growth trajectory and you're not kind of holding something which is just gonna slowly bleed into
55:56
Unidentified speaker (speaker_2): oblivion. So
55:57
Unidentified speaker (UNKNOWN): yeah,
55:58
Unidentified speaker (speaker_2): I'll call it a hold because it's it's so cheap, and maybe you do get an a uptick in, you know. whatever you want to call it, demographics. Um but yeah, it's probably just not
56:08
Unidentified speaker (UNKNOWN): the
56:08
Unidentified speaker (speaker_2): preferred opportunity in this market.
56:10
Andrew Gagan: All right, so an avoid sell.
56:13
Unidentified speaker (speaker_2): Yep, avoid hold.
56:15
Andrew Gagan: Avoid hold. Uh depends which way you look at it. Luke.
56:19
Unidentified speaker (UNKNOWN): Uh
56:20
Unidentified speaker (speaker_1): look, I always struggle to get enthused by these businesses, Andrew. Um I don't mind businesses that acquire to grow, but it's it's it takes 10 seconds looking at a presentation from these guys to see that it's just purely that private to public arbitrage. You know, maybe you get some synergies from a corporate overheads point of view, you know, finance and all that sort of stuff,
56:40
Unidentified speaker (speaker_1): but um, you know, there's no there's no synergies from a brand point of view, there's no synergies um from from an operating point of view. Um and so you know, once that sort sort of slows down and and you get to the top of your your debt limits, you know, you you see exactly what we're seeing on this chart. The earnings have really tapped out around twenty mil NPAT for the last few years. So there's no growth
57:00
Unidentified speaker (speaker_1): as Ben completely uh correctly pointed out. Um you've got a fair bit of debt there. The debt looks pretty maxed out as well. So something can go into another big acquisition to sort of respark some earnings growth. It sort of has to come organically and there's just nothing here. So you know seventeen, 17, eighteen 18 times earnings, it looks okay. You know, it's very defensive, but to me that's a market multiple. And um, you know, do I want to
57:20
Unidentified speaker (speaker_1): pay a market multiple for this business? I'd rather get it a little bit cheaper. So I'll say a sell for this one just doesn't inspire me. Not the sort of business I'd want to own. I'd I'd I'd probably need to see another two or three turns lower on that PE ratio before looking at it for a for a defensive style position.
57:35
Andrew Gagan: All Alright, right, so uh none of us want to use its services. obviously.
57:40
Andrew Gagan: We don't want to be there either, it would seem. Alright, let's uh sum up the second half of the show. The first one brought to us by Ben, it was his suggestion, the Health Co, Healthcare and Wellness REIT. It is a buy from Ben. That's the reason he brought it to us. So you see the huge discount there, particularly to NTA. Um Luke's willing to go along. He he sees the benefits
58:00
Andrew Gagan: there. Um ReadyTech, it is a buy from Luke, whereas Ben would sell it and um has knocked back a takeover bid there. So one to watch.
58:12
Unidentified speaker (UNKNOWN): Uh
58:12
Andrew Gagan: SIG Global, um, Ben's saying, look, a decent business, but um
58:17
Unidentified speaker (UNKNOWN): it
58:17
Andrew Gagan: he calls it a contractor bubble potentially we're in. Um so he would sell it. Luke wouldn't go that far, does acknowledge there are issues there, but uh he would take profit. He would also say. sell motorcycle holdings. A nervous hold from Luke. Um, Ben also willing to hold it, and finally their propelled partners will call it a double sell.
58:36
Unidentified speaker (UNKNOWN): That
58:36
Andrew Gagan: is the show. Thank you to our experts. Ben, thanks for joining us from Seneca Financial Solutions.
58:43
Unidentified speaker (UNKNOWN): Thanks,
58:43
Unidentified speaker (speaker_2): Andrew. Thanks, Luke.
58:44
Andrew Gagan: And Luke, thanks to you. Thanks for joining us in Merryweather Capital. Capitol.
58:48
Unidentified speaker (UNKNOWN): Thanks,
58:48
Unidentified speaker (speaker_1): Jens. Enjoy the weekend.
58:50
Andrew Gagan: You too.
58:51
Andrew Gagan: And thanks to you, of course. Keep sending in your requests.
This page was produced automatically: the audio was transcribed with nvidia/parakeet-tdt-0.6b-v3+sortformer-v2.1 and interpreted by Qwen3.6-35B-A3B-UD-IQ3_S.gguf. Transcription and interpretation can contain errors; always confirm against the original episode. Nothing here is investment advice.

More from The Call from ausbiz

The Call from ausbiz

the call: Monday 16 November

Episode discussion: Pepe and Riaz debate Australian vs US markets, sell Adore Beauty and NAB, buy NextDC and IGO

Speakers’ claims: Philip Pepe and Zach Riaz discuss macroeconomic outlooks, with Pepe favoring Australian equities due to lower valuations and Riaz preferring US markets citing RBA rate hike expectations. They advise selling Adore Beauty and NAB, while recommending buys in NextDC and IGO. Defensive stocks like Coles and Telstra are viewed as expensive or neutral, with Suncorp sold by Pepe but held by Riaz. The hosts also cover AGL, Polynovo, and the AQTY ETF, highlighting sector-specific risks and valuation concerns.

Australian EquitiesUS EquitiesRetail
56 min1 assets20 claims to verify
The Call from ausbiz

the call: Friday 13 November

Episode discussion: Guests discuss NVIDIA CEO resignation, retail sector weakness, and select stock trades across tech, resources, and consumer sectors.

Speakers’ claims: Adam Dawes and Jun Bei Liu analyze market reactions to NVIDIA's CEO resignation, with both viewing the stock as a buy despite long-term founder risk. They contrast views on Lynas Rare Earths and Macquarie Group, citing geopolitical pricing power and compliance fixes respectively. The conversation shifts to consumer discretionary, where both sell Accent Group and Flight Centre due to weak spending and structural threats, while recommending James Hardie for its resilience. Medibank and Bega Cheese are debated based on defensive value versus technical overvaluation.

NVIDIARare EarthsMacquarie Group
52 min1 assets20 claims to verify
All insights